Subscribe To
SNPX / Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?
SNPX News
By InvestorPlace
December 16, 2022
Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?
Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the more_horizontal
By Seeking Alpha
December 9, 2022
Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be
Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work more_horizontal
By PRNewsWire
March 29, 2022
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company more_horizontal
By PRNewsWire
March 22, 2022
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company more_horizontal
By PRNewsWire
March 15, 2022
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutic more_horizontal
By Seeking Alpha
November 16, 2021
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal
By Seeking Alpha
November 16, 2021
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal
By Seeking Alpha
November 16, 2021
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal